Morning Briefing
Summaries of health policy coverage from major news organizations
Expensive Hepatitis Drug Draws Huge Sales
The demand for Gilead Sciences' Sovaldi, which costs $1,000 a pill, indicates how hard it is for insurers to curb the use of life-saving medicines. Meanwhile Humana names a former Goldman Sachs executive as finance chief.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
